Pharma BD Deal Intelligence
Ceftaroline (Teflaro) reached market as promised but never hit the sales projections that justified the price — a durable niche antibiotic, not the blockbuster Forest paid for.
Full analysis, sources & comparables →Ceftaroline is an important late-stage development product that can address serious and life-threatening infections in the hospital setting including MRSA. -…
Forest to acquire privately-held biotech Cerexa for $480M; lead compound ceftaroline anticipated to enter late-stage trials in 2007 with potential market entry…
Forest Labs acquires pharma company Cerexa for up to $580M, including the $480 million upfront and a $100 million milestone tied to ceftaroline sales.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Antibiotics; ceftaroline (Teflaro); $480M + up to $100M milestone
Ceftaroline (Teflaro) reached market as promised but never hit the sales projections that justified the price — a durable niche antibiotic, not the blockbuster Forest paid for.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Forest Laboratories, Inc. / Cerexa Inc. (this deal) | 2006 | $580M | 47 |
| Forest Laboratories, Inc. / Clinical Data, Inc. | 2011 | $1.2B | 37 |
| Forest Laboratories, Inc. / Aptalis Pharma Inc. | 2014 | $2.9B | 25 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |